ME03095B - Derivati benzamida za inhibiranje aktivnosti abl1, abl2 i bcr-abl1 - Google Patents
Derivati benzamida za inhibiranje aktivnosti abl1, abl2 i bcr-abl1Info
- Publication number
- ME03095B ME03095B MEP-2018-117A MEP2018117A ME03095B ME 03095 B ME03095 B ME 03095B ME P2018117 A MEP2018117 A ME P2018117A ME 03095 B ME03095 B ME 03095B
- Authority
- ME
- Montenegro
- Prior art keywords
- abl1
- abl2
- bcr
- inhibiting
- activity
- Prior art date
Links
- 101100268645 Caenorhabditis elegans abl-1 gene Proteins 0.000 title 1
- 150000003936 benzamides Chemical class 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647174P | 2012-05-15 | 2012-05-15 | |
| US201361790967P | 2013-03-15 | 2013-03-15 | |
| PCT/IB2013/053768 WO2013171639A1 (en) | 2012-05-15 | 2013-05-09 | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
| EP13730652.8A EP2861579B9 (en) | 2012-05-15 | 2013-05-09 | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03095B true ME03095B (me) | 2019-01-20 |
Family
ID=48670630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2018-117A ME03095B (me) | 2012-05-15 | 2013-05-09 | Derivati benzamida za inhibiranje aktivnosti abl1, abl2 i bcr-abl1 |
Country Status (50)
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE060743T2 (hu) | 2012-04-26 | 2023-04-28 | Bristol Myers Squibb Co | Gyógyszerészeti kompozíciók, amelyek tartalmaznak imidazothiadiazol- és imidazopiridazinszármazékokat mint proteáz aktívált receptor 4 (PAR4) inhibitorokat trombocitaaggregációk kezelésére |
| JP6078640B2 (ja) * | 2012-05-15 | 2017-02-08 | ノバルティス アーゲー | Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体 |
| NZ701626A (en) | 2012-05-15 | 2016-02-26 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
| CA2871715A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
| CN104334529B (zh) | 2012-05-15 | 2017-03-15 | 诺华股份有限公司 | 用于抑制abl1、abl2和bcr‑abl1的活性的化合物和组合物 |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| KR102403306B1 (ko) | 2013-01-15 | 2022-06-02 | 인사이트 홀딩스 코포레이션 | Pim 키나제 저해제로서 유용한 티아졸카복스아마이드 및 피리딘카복스아마이드 화합물 |
| JP2016528298A (ja) | 2013-08-23 | 2016-09-15 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物 |
| CN106414402A (zh) * | 2013-11-01 | 2017-02-15 | 宇部兴产株式会社 | 丙烯酰(氧基或氨基)五氟硫烷基苯化合物、其药学可接受的盐及其前药 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| EP3623364A1 (en) * | 2014-02-13 | 2020-03-18 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
| SI3116909T1 (sl) | 2014-03-14 | 2020-03-31 | Novartis Ag | Molekule protiteles na LAG-3 in njih uporaba |
| CN106687118A (zh) | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| PE20171067A1 (es) | 2014-10-14 | 2017-07-24 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| CN104478911A (zh) * | 2014-12-19 | 2015-04-01 | 成都安斯利生物医药有限公司 | 一种制备3-三氟甲基吡咯硼酸的方法 |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| WO2016114322A1 (ja) * | 2015-01-13 | 2016-07-21 | 国立大学法人京都大学 | 筋萎縮性側索硬化症の予防及び／又は治療剤 |
| WO2016145102A1 (en) | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene" -dependent signalling |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| JP6878405B2 (ja) | 2015-07-29 | 2021-05-26 | ノバルティス アーゲー | Ｐｄ−１に対する抗体分子を含む組み合わせ治療 |
| EP3317301B1 (en) | 2015-07-29 | 2021-04-07 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| CR20180234A (es) | 2015-11-03 | 2018-09-11 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Ｐｄ−１に対する抗体分子およびその使用 |
| US9931342B2 (en) | 2016-02-02 | 2018-04-03 | Duke University | Compositions and methods for the treatment of cancer |
| WO2017186148A1 (en) * | 2016-04-29 | 2017-11-02 | Astar Biotech Llc | Novel heterocyclic compounds as tyrosine kinase bcr-abl inhibitors |
| US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| JP2019532942A (ja) * | 2016-09-27 | 2019-11-14 | ノバルティス アーゲー | 有機化合物を結晶化させるための界面活性剤系 |
| EP3532047A4 (en) * | 2016-10-26 | 2020-07-01 | The University Of Georgia Research Foundation, Inc | METHODS OF TREATING MYELID LEUKEMIA |
| CA3056356A1 (en) * | 2017-03-15 | 2018-09-20 | Sun Pharma Advanced Research Company Limited | Amorphous dispersion of cyclopropanecarboxylic acid (5-{5-[n'-(2- chloro-6-methylbenzoyl) hydrazinocarbonyl]-2-methyl-phenylethynyl}-pyridin-2-yl) amide |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| WO2018216705A1 (ja) * | 2017-05-23 | 2018-11-29 | 国立大学法人京都大学 | 神経変性疾患の予防及び／又は治療剤 |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| JP2021509907A (ja) | 2018-01-09 | 2021-04-08 | リガンド・ファーマシューティカルズ・インコーポレイテッド | アセタール化合物およびその治療的使用 |
| WO2019204354A1 (en) * | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| KR102618168B1 (ko) * | 2018-07-06 | 2023-12-27 | 일양약품주식회사 | 프리온 질환의 예방 또는 치료를 위한 약제학적 조성물 |
| KR102119150B1 (ko) | 2018-10-23 | 2020-06-04 | 한국원자력의학원 | N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물 |
| US11407735B2 (en) * | 2019-05-16 | 2022-08-09 | Novartis Ag | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
| US11236070B2 (en) | 2019-05-16 | 2022-02-01 | Novartis Ag | Chemical process |
| GB201913110D0 (en) * | 2019-09-11 | 2019-10-23 | Benevolentai Bio Ltd | New compounds and methods |
| JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
| CN114728943A (zh) * | 2020-01-19 | 2022-07-08 | 正大天晴药业集团股份有限公司 | 作为bcr-abl抑制剂的化合物 |
| EP4353230A3 (en) | 2020-01-28 | 2024-06-19 | Teva Pharmaceuticals International GmbH | Solid state forms of asciminib and process for preparation thereof |
| US20230072528A1 (en) | 2020-02-05 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki) |
| CN111321200A (zh) * | 2020-02-28 | 2020-06-23 | 广州安镝声生物医药科技有限公司 | 一种细胞外abl1激酶活性检测试剂盒及其应用 |
| CN115124551B (zh) * | 2021-03-24 | 2024-04-30 | 奥锐特药业(天津)有限公司 | 一种高纯度米哚妥林的制备方法 |
| WO2022206937A1 (zh) * | 2021-04-01 | 2022-10-06 | 苏州晶云药物科技股份有限公司 | 一种吡唑取代的烟酰胺类化合物的盐酸盐新晶型及其制备方法 |
| IL308095A (en) | 2021-05-11 | 2023-12-01 | Novartis Ag | Dosing regimens |
| IL308614A (en) * | 2021-05-28 | 2024-01-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | A compound used as a BCR-ABL inhibitor |
| CN114149409B (zh) * | 2021-11-16 | 2024-03-22 | 中国药科大学 | 一种具有蛋白激酶抑制活性的（杂）芳基酰胺类化合物 |
| CN116135851A (zh) * | 2021-11-17 | 2023-05-19 | 武汉众诚康健生物医药科技有限公司 | 一种芳香胺化合物及其应用 |
| EP4447968A2 (en) * | 2021-12-13 | 2024-10-23 | The Regents Of The University Of California | Abl inhibitors and uses thereof |
| CN115109048B (zh) * | 2022-08-10 | 2023-12-08 | 中国药科大学 | 一种(杂)芳基酰胺类化合物 |
| WO2024100212A1 (en) | 2022-11-10 | 2024-05-16 | Synthon B.V. | Crystalline form of asciminib hydrochloride |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
| US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
| US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| DE2845997A1 (de) | 1978-10-23 | 1980-04-30 | Bayer Ag | Pflanzenwachstumsregulierende mittel, verfahren zu ihrer herstellung und ihre verwendung zur regulierung des pflanzenwachstums |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| BR8807217A (pt) | 1987-09-23 | 1989-10-17 | Hoffmann La Roche | Compostos heterocilicos |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| JP2001500851A (ja) | 1996-08-30 | 2001-01-23 | ノバルティス アクチエンゲゼルシャフト | エポシロンの製造法および製造過程中に得られる中間生産物 |
| CA2264908C (en) | 1996-09-06 | 2006-04-25 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
| HU229833B1 (en) | 1996-11-18 | 2014-09-29 | Biotechnolog Forschung Gmbh | Epothilone d production process, and its use as cytostatic as well as phytosanitary agents |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| NZ506742A (en) | 1998-02-25 | 2003-09-26 | Sloan Kettering Inst Cancer | Synthesis of desoxyepothilones and hydroxy acid derivative intermediates |
| ATE459616T1 (de) | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
| NZ511722A (en) | 1998-11-20 | 2004-05-28 | Kosan Biosciences Inc | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| JP2003520854A (ja) | 2000-01-27 | 2003-07-08 | サイトビア インコーポレイテッド | カスパーゼのアクチベーターおよびアポトーシスのインデューサーとしての置換ニコチンアミドおよび類似物およびそれらの使用 |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| WO2003039529A1 (en) | 2001-11-07 | 2003-05-15 | 4Sc A.G. | Selective antibacterial agents |
| AU2002367087A1 (en) | 2001-12-21 | 2003-07-15 | 7Tm Pharma A/S | Method for the treatment of mc receptor related disorders with a chelate and/or a chelator |
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| JP4896518B2 (ja) | 2002-12-13 | 2012-03-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | ニコチンアミド系キナーゼ阻害薬 |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US20080167347A1 (en) | 2005-01-20 | 2008-07-10 | Shiongi & Co., Ltd. | Ctgf Expression Inhibitor |
| WO2006120178A1 (en) | 2005-05-11 | 2006-11-16 | Novo Nordisk A/S | New haloalkylsulfone substituted compounds useful for treating obesity and diabetes |
| WO2007002441A1 (en) | 2005-06-24 | 2007-01-04 | Emory University | Methods of use for non-atp competitive tyrosine kinase inhibitors to treat pathogenic infection |
| DK1746097T3 (da) | 2005-07-20 | 2010-05-25 | Aventis Pharma Sa | 1,4-dihydropyridin-kondenserede heterocykliske ringe, fremgangsmåde til fremstilling af disse, anvendelse og sammensætninger, der indeholder dem |
| KR20080109068A (ko) * | 2006-04-05 | 2008-12-16 | 노파르티스 아게 | 암을 치료하기 위한 ｂｃｒ-ａｂｌ/ｃ-ｋｉｔ/ｐｄｇｆ-ｒ ｔｋ 억제제를 포함하는 조합물 |
| WO2008021725A2 (en) | 2006-08-11 | 2008-02-21 | Smithkline Beecham Corporation | Chemical compounds |
| CN101528744A (zh) | 2006-10-20 | 2009-09-09 | Irm责任有限公司 | 用于调节c-kit和pdgfr受体的组合物和方法 |
| US7939690B2 (en) * | 2006-11-15 | 2011-05-10 | High Point Pharmaceuticals, Llc | Haloalkylsulfone substituted compounds useful for treating obesity and diabetes |
| EP2111402B1 (en) * | 2007-01-05 | 2012-03-07 | Bristol-Myers Squibb Company | Aminopyrazole kinase inhibitors |
| WO2008112695A2 (en) | 2007-03-12 | 2008-09-18 | Irm Llc | Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment |
| WO2008124393A1 (en) | 2007-04-04 | 2008-10-16 | Irm Llc | Benzothiazole derivatives and their use as protein kinase inhibitors |
| WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| JP2010535172A (ja) | 2007-08-02 | 2010-11-18 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｎｓ障害の処置のためのベンズアミド誘導体の使用 |
| KR101552474B1 (ko) | 2007-09-17 | 2015-09-11 | 애브비 바하마스 리미티드 | Ｃ형 간염 치료용 우라실 또는 티민 유도체 |
| WO2009152356A2 (en) | 2008-06-11 | 2009-12-17 | Irm Llc | Compounds and compositions useful for the treatment of malaria |
| CA2738448A1 (en) | 2008-09-29 | 2010-04-01 | Boehringer Ingelheim International Gmbh | New chemical compounds |
| CN102548987B (zh) | 2009-07-14 | 2014-04-16 | 江苏迈度药物研发有限公司 | 作为激酶抑制剂的氟取代化合物及其使用方法 |
| JP2011057661A (ja) | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| CN102811619B (zh) | 2009-11-13 | 2015-04-22 | 金纳斯克公司 | 激酶抑制剂 |
| JO3634B1 (ar) * | 2009-11-17 | 2020-08-27 | Novartis Ag | طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| AU2011210116B2 (en) | 2010-01-29 | 2014-02-06 | Catholic University Industry Academic Cooperation Foundation | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| CN102276500A (zh) * | 2011-05-05 | 2011-12-14 | 西安交通大学 | 水杨酰胺类抗肿瘤化合物及其合成方法和用途 |
| PT2713722T (pt) | 2011-05-31 | 2017-06-27 | Receptos Llc | Novos estabilizadores e moduladores do receptor glp-1 |
| NZ701626A (en) * | 2012-05-15 | 2016-02-26 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
| JP6078640B2 (ja) * | 2012-05-15 | 2017-02-08 | ノバルティス アーゲー | Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体 |
| CA2871715A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
| CN104334529B (zh) * | 2012-05-15 | 2017-03-15 | 诺华股份有限公司 | 用于抑制abl1、abl2和bcr‑abl1的活性的化合物和组合物 |
-
2013
- 2013-05-09 NZ NZ701626A patent/NZ701626A/en unknown
- 2013-05-09 MY MYPI2014703394A patent/MY169377A/en unknown
- 2013-05-09 GE GEAP201313621A patent/GEP201606532B/en unknown
- 2013-05-09 CA CA2868958A patent/CA2868958C/en active Active
- 2013-05-09 BR BR112014026383-3A patent/BR112014026383B1/pt active IP Right Grant
- 2013-05-09 TR TR2018/07023T patent/TR201807023T4/tr unknown
- 2013-05-09 JP JP2015512169A patent/JP6078639B2/ja active Active
- 2013-05-09 LT LTEP13730652.8T patent/LT2861579T/lt unknown
- 2013-05-09 AP AP2014007992A patent/AP3613A/xx active
- 2013-05-09 SI SI201330997T patent/SI2861579T1/en unknown
- 2013-05-09 EP EP13730652.8A patent/EP2861579B9/en active Active
- 2013-05-09 ES ES13730652.8T patent/ES2670601T3/es active Active
- 2013-05-09 AU AU2013261127A patent/AU2013261127B2/en active Active
- 2013-05-09 PT PT137306528T patent/PT2861579T/pt unknown
- 2013-05-09 PE PE2014002006A patent/PE20150669A1/es not_active Application Discontinuation
- 2013-05-09 ME MEP-2018-117A patent/ME03095B/me unknown
- 2013-05-09 HU HUE13730652A patent/HUE039138T2/hu unknown
- 2013-05-09 WO PCT/IB2013/053768 patent/WO2013171639A1/en active Application Filing
- 2013-05-09 PE PE2016001014A patent/PE20161416A1/es unknown
- 2013-05-09 RS RS20180497A patent/RS57177B1/sr unknown
- 2013-05-09 MX MX2014013374A patent/MX359014B/es active IP Right Grant
- 2013-05-09 PL PL13730652T patent/PL2861579T3/pl unknown
- 2013-05-09 CN CN201380025539.6A patent/CN104302638B/zh active Active
- 2013-05-09 DK DK13730652.8T patent/DK2861579T5/da active
- 2013-05-09 SG SG11201407152XA patent/SG11201407152XA/en unknown
- 2013-05-09 CU CUP2014000131A patent/CU24265B1/es unknown
- 2013-05-09 EA EA201491824A patent/EA024391B1/ru not_active IP Right Cessation
- 2013-05-09 PE PE2020000185A patent/PE20210667A1/es unknown
- 2013-05-09 MA MA37519A patent/MA37519B1/fr unknown
- 2013-05-09 KR KR1020147031773A patent/KR102091893B1/ko active Protection Beyond IP Right Term
- 2013-05-13 US US13/892,769 patent/US8829195B2/en active Active
- 2013-05-15 UY UY0001034811A patent/UY34811A/es active IP Right Grant
- 2013-05-15 AR ARP130101692A patent/AR091063A1/es active IP Right Grant
- 2013-05-15 JO JOP/2013/0150A patent/JO3453B1/ar active
- 2013-05-15 TW TW102117263A patent/TWI560183B/zh active
- 2013-09-05 UA UAA201412051A patent/UA113208C2/uk unknown
-
2014
- 2014-07-31 US US14/448,363 patent/US20140343086A1/en not_active Abandoned
- 2014-09-29 ZA ZA2014/07065A patent/ZA201407065B/en unknown
- 2014-10-13 TN TN2014000427A patent/TN2014000427A1/fr unknown
- 2014-10-14 CL CL2014002757A patent/CL2014002757A1/es unknown
- 2014-11-06 IL IL235566A patent/IL235566A/en active IP Right Grant
- 2014-11-12 DO DO2014000256A patent/DOP2014000256A/es unknown
- 2014-11-13 PH PH12014502531A patent/PH12014502531A1/en unknown
- 2014-11-14 CO CO14252517A patent/CO7131380A2/es unknown
- 2014-11-14 SV SV2014004850A patent/SV2014004850A/es unknown
- 2014-11-14 CR CR20140519A patent/CR20140519A/es unknown
- 2014-11-14 GT GT201400253A patent/GT201400253A/es unknown
-
2015
- 2015-04-24 HK HK15103981.8A patent/HK1203495A1/xx unknown
-
2018
- 2018-05-03 HR HRP20180695TT patent/HRP20180695T1/hr unknown
- 2018-05-18 CY CY20181100518T patent/CY1120235T1/el unknown
-
2022
- 2022-10-20 FR FR22C1053C patent/FR22C1053I2/fr active Active
- 2022-10-25 HU HUS2200046C patent/HUS2200046I1/hu unknown
- 2022-10-25 NO NO2022043C patent/NO2022043I1/no unknown
- 2022-10-26 NL NL301201C patent/NL301201I2/nl unknown
- 2022-11-02 CY CY2022033C patent/CY2022033I1/el unknown
- 2022-11-10 LT LTPA2022523C patent/LTPA2022523I1/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2200046I1 (hu) | Benzamidszármazékok ABL1, ABL2 és BCR-ABL1 aktivitás gátlására | |
| HK1217487A1 (zh) | 用於治療成癮的作為乙醛脫氫酶- 抑制劑的 -氧基- -二氫-吡啶- -基 -芐基 -苯甲酰胺衍生物 | |
| HUE039664T2 (hu) | N-Arilamidinnel szubsztituált trifluoretil-szulfid-származékok mint atka- és rovarirtószerek | |
| ZA201503457B (en) | Active compound combinations comprising carboxamide derivatives and a biological control agent | |
| HK1196819A1 (zh) | 雜環化合物、含有所述化合物的藥物及其用途和其製備方法 | |
| IL233529A0 (en) | 1, 5-naphthyridine derivatives and malac inhibitors containing them | |
| IL235681A (en) | 5-amino [1, 4] thiazines as 1bace inhibitors | |
| EP2802324A4 (en) | BENZHYDROL-PYRAZOLE DERIVATIVES HAVING KINASE INHIBITING ACTIVITY AND USES THEREOF | |
| HUE050104T2 (hu) | 3,5N-trihidroxi-alkánamid és származékok: eljárás ennek elõállítására és ennek felhasználása | |
| HK1203848A1 (en) | Tryptoline derivatives having kinase inhibitory activity and uses thereof tryptoline | |
| TH1401006797A (th) | อนุพันธ์เบนซาไมด์สำหรับการยับยั้งสภาพออกฤทธิ์ของ abl1, abl2 และ bcr-abl1 | |
| LT2908643T (lt) | Veikliojo junginio deriniai, apimantys karboksamido darinius ir biologinės kontrolės agentą | |
| PL395184A1 (pl) | Nowe pochodne benzimidazolu, sposób wytwarzania i zastosowanie pochodnych benzimidazolu |